G1 Therapeutics Inc (GTHX.OQ)
GTHX.OQ on NASDAQ Stock Exchange Global Select Market
62.94USD
18 Sep 2018
62.94USD
18 Sep 2018
Change (% chg)
-- (--)
-- (--)
Prev Close
$62.94
$62.94
Open
--
--
Day's High
--
--
Day's Low
--
--
Volume
--
--
Avg. Vol
103,283
103,283
52-wk High
$69.23
$69.23
52-wk Low
$18.45
$18.45
About
G1 Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in developing small-molecule therapies for the treatment of cancer. Its two clinical-stage candidates are trilaciclib (G1T28) and G1T38, which are potent, selective inhibitors of the validated kinase targets CDK4/6. Trilaciclib and G1T38... (more)
Overall
| Beta: | -- |
| Market Cap(Mil.): | $2,102.48 |
| Shares Outstanding(Mil.): | 33.40 |
| Dividend: | -- |
| Yield (%): | -- |
Financials
| GTHX.OQ | Industry | Sector | |
|---|---|---|---|
| P/E (TTM): | -- | 103.50 | 32.14 |
| EPS (TTM): | -2.55 | -- | -- |
| ROI: | -49.19 | 1.52 | 12.66 |
| ROE: | -49.20 | 0.25 | 14.84 |
BRIEF-G1 Therapeutics Reports Qtrly Loss Per Share Of $0.70
* G1 THERAPEUTICS PROVIDES FIRST QUARTER 2018 CORPORATE AND FINANCIAL UPDATE
Estimates